Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder

19:39 EDT 22nd May 2015 | BioPortfolio

Summary

This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Major Depressive Disorder

Intervention

Antidepressant + placebo, Antidepressant + cariprazine (0.1-0.3 mg/day), Antidepressant + cariprazine (1-2 mg/d)

Location

Forest Investigative Site 040
Phoenix
Arizona
United States
85050

Status

Completed

Source

Forest Laboratories

Results (where available)

View Results

Links

Clinical Trials [781 Associated Clinical Trials listed on BioPortfolio]

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatmen...

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatmen...

Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis

This is a retrospective chart review study to determine if Deplin® 7.5mg-15mg combined with an antidepressant is better than an antidepressant alone in adults with major depression.

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders

The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to...

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.

PubMed Articles [7916 Associated PubMed Articles listed on BioPortfolio]

Antidepressant augmentation with anti-inflammatory agents.

Antidepressant augmentation strategies are commonly employed to treat depressed patients who do not respond to antidepressant monotherapy. Neuroinflammatory mechanisms have been implicated in depressi...

Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.

Aprepitant is a neurokinin 1 receptor antagonist approved for prevention of chemotherapy-induced and post-operative nausea and vomiting. Early studies demonstrated promising antidepressant activity as...

Antidepressant use and the risk of suicide: A population-based cohort study.

The existing literature provides contradictory evidence on antidepressant use and risk of suicide. Some studies have shown that the use of Selective Serotonin Reuptake Inhibitors (SSRIs) is associated...

Dynamics of melanin-concentrating hormone (MCH) serum levels in major depressive disorder during antidepressant treatment.

In preclinical studies, the hypothalamic polypeptide melanin-concentrating hormone (MCH) has been shown to be involved in depression-like behavior and modulations of MCH and MCH-receptors were propose...

Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients.

Whether the Brain Derived Neurotrophic Factor (BDNF) Val66Met polymorphism can predict antidepressant drug efficacy in depressed patients remains unclear, suggesting that it may depend on antidepressa...

Medical and Biotech [MESH] Definitions

A phosphodiesterase inhibitor with antidepressant properties.

A tricyclic antidepressant with some tranquilizing action.

A tricyclic antidepressant with actions similar to AMITRIPTYLINE.

The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.

A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.

More From BioPortfolio on "Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder"

Search BioPortfolio:
Loading
Advertisement
Advertisement

Searches Linking to this Trial